BAP Council Member Details

Council Member

Dr Paul Stokes

Paul Stokes

King’s College London
Council Member until 2020

Dr Stokes is a Clinical Senior Lecturer in Mood Disorders at the Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King’s College London and an Honorary Consultant Psychiatrist, South London and Maudsley NHS Foundation Trust.

Dr Stokes studied medicine at the University of Birmingham and completed clinical training in Psychiatry at the Maudsley Hospital, London. In his doctoral studies at Imperial College London, Dr Stokes used PET and fMRI neuroimaging to examine the role of neurotransmitter systems in mediating psychosis, addictions and mood disorders. Dr Stokes obtained his PhD in 2011 from Imperial College London and was awarded the 2013 Royal Society of Medicine Psychiatry Section Mental Health Research Prize. Dr Stokes joined the Centre for Affective Disorders in 2013 where his main research interest is to use neuroimaging to better understand the neurochemical brain mechanisms which mediate bipolar disorder and related co-morbid addictions. He is also very interested in the use of clinical trials and functional neuroimaging to assess treatments to improve mood and cognitive symptoms in mood disorders. Dr Stokes is the NIHR CRN South London lead for Mental Health and the BRC Maudsley Industry and Strategic Alliance champion.

In his clinical work, Dr Stokes is a consultant psychiatrist with the National Affective Disorders Service at the Maudsley Hospital (a national specialist service for people with treatment resistant mood disorders) and is a specialist consultant psychiatric advisor in mood disorders for the United Kingdom Civil Aviation Authority.

Dr Stokes was elected to the British Association for Psychopharmacology governing council in 2016 and is a member of the RCPsych Psychopharmacology committee. He is the Frontiers in Psychiatry Specialty Chief Editor for Mood and Anxiety disorders.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. Dr Stokes attended an advisory board on the treatment of depression hosted by Liva Nova
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Dr Stokes received a research grant for the purchase of medication and other expenses for a pharmacological fMRI study from Corcept Therapeutics. Dr Stokes has received grant funding from the Medical Research Council UK for a collaborative study with Janssen Research and Development LLC. Janssen Research and Development LLC are providing non-financial contributions to support this study.
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. Corcept Therapeutics Inc fully funded attendance at their internal conference in California USA and all related expenses
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. No
  21. If there is anything else you feel it necessary to disclose, please provide details below:

Form completed on 20th September 2018